Surgical Debulking of Pituitary Adenomas

Status Completed

Clinical Trial Summary

Purpose:

The primary objective of this trial will be to determine whether surgery (debulking of pituitary adenomas) improves the response of patients with acromegaly to treatment with Octreotide LAR, when compared to Octreotide LAR therapy alone.

Background:

The current goal of treatment for people with acromegaly is normalization of both growth hormone (GH) and insulin-like-growth-factor-1 (IGF-1) levels. Normalization of GH and IGF-1 levels attenuates the morbidity (hypertension, cardiovascular disease, sleep apnea, increased cancer risk, arthritis) and increased mortality associated with persistent GH and IGF-1 elevation. The optimal approach to achieving these goals in patients with pituitary macroadenomas remains controversial. Available treatment modalities include transsphenoidal hypophysectomy, medical therapy (somatostatin analogues and/or dopaminergic agonists), radiotherapy, or a combination or these interventions. No randomized trials have been conducted to investigate whether surgical debulking of pituitary macroadenomas enhances the efficacy of medical therapy. This study is designed to rigorously investigate whether surgical debulking increases the efficacy of a long-acting depot somatostatin preparation, Sandostatin LAR, so that evidence-based optimal care may be offered to patients with acromegaly.

Study Design:

This is a randomized, multicenter trial. A total of 69 patients from 6 or more centers will be enrolled and complete the study. Stratification will be done by a single radiologist at the coordinating center (NYU), and patients with comparable disease will be randomized to Sandostatin LAR treatment administered 1 time per month by IM injection for 3 months before (Arm A) or, for non-cured patients, after (Arm B) surgery. All patients will undergo transsphenoidal hypophysectomy. The impact of surgical debulking on responsiveness to Sandostatin LAR will be evaluated.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01371643
Study type	Interventional
Source	New York University School of Medicine
Contact
Status	Completed
Phase	Phase 4
Start date	April 2004
Completion date	December 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04081701` - 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.	Phase 4
Completed	`NCT01689064` - Comparison of Surgical Approach to Endoscopic Pituitary Adenoma Resection	N/A
Recruiting	`NCT04611685` - Pain Management After Transnasal Transsphenoidal Surgery for Pituitary Adenomas	N/A
Completed	`NCT04212793` - Detection of PitNET Tissue During TSS Using Bevacizumab-800CW	Phase 1
Recruiting	`NCT02709863` - Comparison of The Effects of Sevoflurane, Desflurane and Total Intravenous Anaesthesia on Pulmonary Function Tests	N/A
Completed	`NCT01465672` - Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis	N/A
Terminated	`NCT00798057` - Proton Radiation Therapy for Pituitary Adenoma	N/A
Completed	`NCT01504399` - Rhinological Outcomes in Endonasal Pituitary Surgery
Recruiting	`NCT01556230` - Prospective Study of Clinically Nonfunctioning Pituitary Adenomas
Completed	`NCT04074642` - OCT-angiography as a Pronostic Marker for Visual Impairment in Patients Undergoing Neurosurgery for Compressive Macroadenoma : a Prospective Study.	N/A
Recruiting	`NCT04621565` - Hydrocortisone Use During Peri-operation for Pituitary Adenomas	N/A
Completed	`NCT04076046` - Multicentric Prospective Validation of the Zurich Pituitary Score
Not yet recruiting	`NCT03714763` - Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)	N/A
Recruiting	`NCT05822817` - Comparison of Postoperative Recovery of Sevoflurane and Propofol After Transsphenoidal Surgery	Phase 4
Recruiting	`NCT03164148` - Heart Rate Variability (HRV) in Pituitary Adenoma	N/A
Completed	`NCT04284605` - Effects Exercise Training in Patients With Pituitary Adenoma	N/A
Terminated	`NCT03515603` - Endocrine Outcome of Surgery for Pituitary Adenoma	N/A
Not yet recruiting	`NCT04863456` - Efficiency and Safety of Different Treatment Strategies in Adults With Pituitary Adenomas With Hypothalamic Involvement	N/A
Active, not recruiting	`NCT03465618` - A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors	Phase 1
Completed	`NCT02727686` - Post-Operative Water Load Following Transsphenoidal Pituitary Surgery	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.